Aurobindo Pharma receives final approval for Meropenem Injection
From USFDA
Aurobindo Pharma has received final approval from the US Food and Drug Administration to manufacture and market Meropenem Injection 500 mg/vial and 1 g/vial. Aurobindo's Meropenem injection is a generic equivalent of AstraZeneca Pharmaceuticals' Merrem injection. The product will be launched in April 2017.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content